cyclooxygenase

(redirected from Cox-2)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Cox-2: Cox-1

cyclooxygenase

[‚sī·klō′äks·ə·jə‚nās]
(biochemistry)
An enzyme that catalyzes the conversion of arachidonic acid into prostaglandins.
Mentioned in ?
References in periodicals archive ?
that really deserves some attention," says Raymond DuBois, a COX-2 researcher at Vanderbilt-Ingram Cancer Center in Nashville.
For example, if the cox-2 inhibitors are only marginally more expensive than current prescription NSAIDs, then the cost impact of converting to cox-2 inhibitors would be relatively minimal.
Detailed analysis of the FDA and EMEA evaluations of the Cox-2s, including a review of the three day FDA advisory committee meeting held in February and analysis of the main conclusion with respect to the impact on current and future treatments, are provided.
But there remains a patient population for whom no effective alternative to COX-2 Inhibitors is available today.
There is no reason to think that inhibition of Cox-2 would not work [against] esophagus or stomach cancer, if it works in the colon," Ristimiiki says.
Mark's Hospital in London are studying whether COX-2 inhibitors prevent the formation of sometimes precancerous growths called polyps.
Physicians' reluctance to prescribe Cox-2 inhibitors for pain therapy is increasing," remarks Perez.
Frost & Sullivan will hold this conference call at 2:00 pm (CST) / 3:00 pm (EST) on Wednesday, December 15, 2004, which will provide industry participants an outlook of the Cox-2 inhibitors market.
During the 1970s it became apparent that multiple COX isoenzymes may exist and this led to the eventual cloning of COX-1 and COX-2 in the 1990s.
Evaluate pharmacological and clinical data surrounding Vioxx, remaining COX-2 inhibitors on the market, and drugs in development
Throughout 2003, Prime evaluated the members who were denied a Cox-2 drug and started taking an NSAID as a result of the pre-authorization program.
As a result, estimates of COX-2 cost effectiveness assumed - based on expert opinion - that most physicians prescribing COX-2 drugs would either stop or dramatically reduce their prescribing of a second drug to protect the gastrointestinal system, which occurs approximately 25% of the time when traditional NSAIDs are prescribed.